Despite decreasing rates of alcohol and tobacco use during pregnancy, the use of cannabis use during pregnancy is on the rise. According to data collected from the National Survey on Drug Use and Health, the use of cannabis in pregnant women aged 18 to 44 years rose from 2.37% in 2002 to 3.85% in 2014… Read More »
It seems that there is considerable variation in the estimated prevalence of suicidal ideation in pregnant and postpartum women across studies. One element that may contribute to this variation is how we assess for this symptom. Many studies use self-report questionnaires, such as the Edinburgh Postnatal Depression Scale (EPDS) which asks how often “the thought… Read More »
Print this page SUMMIT, N.J.–(BUSINESS WIRE) July 19, 2019 — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the… Read More »
FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Print this page DUBLIN, March 20, 2019 /PRNewswire/ — Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive… Read More »
December 24, 2018 This article originally appeared here. Share this content: As appropriate initial antifungal therapy has been found to be critical, upfront combination antifungal therapy may be required to increase the probability of survival of patients at risk for invasive Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible… Read More »